When to Start Teriparatide
Teriparatide should be initiated in postmenopausal women with osteoporosis at very high risk of fracture, specifically those with severe or multiple vertebral fractures, recent fracture (within 12 months), very low BMD (T-score ≤ -3.5), or failure of bisphosphonate therapy. 1, 2, 3
Patient Selection Criteria
The most recent 2023 American College of Physicians guideline provides the clearest framework for initiating teriparatide 1:
Very High Risk Patients (First-Line Indication)
- Older age (mean >74 years in pivotal trials)
- Recent fracture within the past 12 months
- Multiple clinical osteoporotic fractures (history of ≥2 fractures)
- Severe vertebral fractures or multiple vertebral fractures
- Failure of other osteoporosis therapy (continued bone loss or new fractures on bisphosphonates)
- Very low BMD (T-score ≤ -3.5, particularly in patients <65 years) 4
FDA-Approved Indications
The FDA label specifies three populations 3:
- Postmenopausal women with osteoporosis at high risk for fracture or who have failed/are intolerant to other therapies
- Men with primary or hypogonadal osteoporosis at high risk for fracture or who have failed/are intolerant to other therapies
- Men and women with glucocorticoid-induced osteoporosis at high risk for fracture or who have failed/are intolerant to other therapies
Treatment Algorithm
Step 1: Risk Stratification
Identify patients at very high risk rather than simply "high risk." The distinction is critical—teriparatide is conditionally recommended only for very high-risk patients, not all high-risk patients 1.
Step 2: Consider Treatment Sequence
- Treatment-naive patients: Teriparatide can be first-line in very high-risk patients 2, 5
- Prior bisphosphonate users: Teriparatide remains effective but may have slightly delayed onset and blunted magnitude of effect 2. The VERO trial subgroup analysis showed similar fracture reductions in prior bisphosphonate users versus treatment-naive patients 2
Step 3: Pre-Treatment Requirements
Before initiating teriparatide:
- Check serum calcium (contraindicated if elevated) 2, 3
- Ensure adequate supplementation: 1000 mg calcium + 400-800 IU vitamin D daily 1, 3
- Screen for contraindications (see below)
Critical Treatment Parameters
Duration
- Maximum 2 years of treatment during a patient's lifetime 2, 3
- Use beyond 2 years should only be considered if patient remains at or returns to very high fracture risk 3
Sequential Therapy (Essential)
Teriparatide MUST be followed by antiresorptive therapy 1, 2. This is non-negotiable because:
- Benefits are rapidly lost after discontinuation (within 1 year) 2
- Bone loss accelerates without subsequent antiresorptive treatment
- Options for sequential therapy: bisphosphonates, denosumab, raloxifene, or hormone therapy 2
Administration
- 20 mcg subcutaneous injection daily 3
- Administer into thigh or abdomen 3
- Initial doses should be given where patient can sit/lie down due to orthostatic hypotension risk 3
Contraindications and Cautions
Absolute Contraindications 3
- Hypersensitivity to teriparatide
- Open epiphyses (pediatric use contraindicated)
- Paget's disease or other metabolic bone diseases
- Bone metastases or skeletal malignancies
- Prior skeletal radiation therapy
- Hereditary disorders predisposing to osteosarcoma
- Pre-existing hypercalcemia
Relative Contraindications
Common Pitfalls to Avoid
Using teriparatide in standard "high risk" rather than "very high risk" patients: The 2023 ACP guideline is explicit that this is a conditional recommendation for very high-risk patients only 1
Failing to plan sequential therapy: Not arranging antiresorptive follow-up negates the benefits of teriparatide 2
Combining with bisphosphonates: Concurrent use is not recommended and may blunt teriparatide's anabolic effect 2, 4
Inadequate calcium/vitamin D supplementation: Ensure 1000 mg calcium and 400-1000 IU vitamin D daily 1, 3, 4
Not monitoring serum calcium: Check at baseline and after 1 month of treatment 3, 4
Gender Considerations
The 2023 ACP guideline notes that evidence for males was insufficient to make a recommendation due to indirectness 1. However, the 2019 Endocrine Society guideline and FDA label support use in men with primary or hypogonadal osteoporosis at very high risk 2, 3. The evidence base is stronger for postmenopausal women.
Expected Outcomes
- Vertebral fractures by 65-69% (high certainty)
- Clinical fractures by 27 per 1000 patients (high certainty)
- Nonvertebral fractures by 35-50% 6
Effects become evident at 8-12 months of treatment 6.